VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.27 USD | -2.93% |
|
-8.19% | +10.30% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -452M | Net income 2025 * | -507M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-17.3
x | P/E ratio 2025 * |
-16
x | Employees | 254 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxcyte, Inc.
More recommendations
More press releases
More news
| 1 day | -2.93% | ||
| 1 week | -8.19% | ||
| Current month | +14.40% | ||
| 1 month | +13.78% | ||
| 3 months | -9.89% | ||
| 6 months | +41.37% | ||
| Current year | +10.30% |
1 week
68.26
76.00
1 month
58.1076.00
Current year
53.8382.04
1 year
44.2082.04
3 years
16.7882.04
5 years
15.5182.04
10 years
15.5182.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 13-05-26 |
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
| Director of Finance/CFO | 55 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
Anne Drapeau
BRD | Director/Board Member | 57 | 21-09-15 |
Heath Lukatch
BRD | Director/Board Member | 56 | 18-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.27% | 0 M€ | 0.00% | - | |
| 0.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 69.27 | -2.93% | 577,112 |
| 24-05-22 | 71.36 | -3.11% | 654,155 |
| 24-05-21 | 73.65 | -3.00% | 550,440 |
| 24-05-20 | 75.93 | +1.82% | 617,897 |
| 24-05-17 | 74.57 | -1.17% | 688,017 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
69.27
USD
Average target price
103.1
USD
Spread / Average Target
+48.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.30% | 7.54B | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.09% | 21.58B | |
| -10.53% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- PCVX Stock
